GHGuoyu Hu

Guoyu Hu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Guoyu Hu has a total of 31 co-authors. Here are the top co-authors by number of shared publications:

  • Yuan Chen

    Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan, China

    6 shared publications
  • Hu Zhao

    Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan, China

    5 shared publications
  • Jing Luo

    Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan, China

    4 shared publications
  • Hai-Mei Chen

    XiangYa School of Medicine, Department of Hematology, Central South University, The Affiliated Zhuzhou Hospital, Zhuzhou, China

    2 shared publications
  • Kui Tan

    Department of Hematology, The Affiliated Zhuzhou Hospital Xiangya Medical College CSU, Zhuzhou, Hunan 412000, P.R. China

    2 shared publications
  • Lai Yi

    XiangYa School of Medicine, Department of Hematology, Central South University, The Affiliated Zhuzhou Hospital, Zhuzhou, China

    2 shared publications

Latest Publications

  • Open Access

    PSXII-9 Identifying Selection Signatures for Immune Response and Resilience to Aleutian Disease in Mink Using Genotypes Data

    by Guoyu Hu, Duy Ngoc Do, Ghader Manafiazar, Alyson Ann Kelvin, Graham Plastow, Mehdi Sargolzaei, Zhiquan Wang, Younes Miar

    Aleutian disease (AD), a severe immune-complex disease, brings tremendous financial losses to the mink industry. Resilience is the ability of an animal to minimize the influences caused by disturbances and maintain its performance under pathogen exposure. Many AD-positive farms have selected AD-resilient mink based on AD tests and/or AD-resilience indicator traits, such as growth, pelt quality, and reproduction. Selection based on these indicator traits may have changed the patterns of genetic variation and potentially represent a genomic signature that can be used to identify genes subjected to selection. Therefore, the main objective of this study was to identify the selection signatures related to immune response (IRE) and resilience to AD. . A total of 1,411 mink in five color types (black, demi, mahogany, pastel, and stardust) from the Canadian Centre for Fur Animal Research (Truro, Nova Scotia, Canada), which is an AD-positive facility, were genotyped using the Axiom Affymetrix Mink 70K single nucleotide polymorphism (SNP) panel. For the IRE trait, 264 mink were grouped into pairwise groups based on the combined results of counter-immunoelectrophoresis (CIEP) and enzyme-linked immunosorbent assay (ELISA) tests. Individuals in black (n = 29), demi (n = 131), mahogany (n = 76), and pastel (36) color types were also grouped based on combined results of CIEP and ELISA tests, respectively. For resilience traits, two methods were used to group CIEP-positive individuals into pairwise groups: 1) based on their general resilience performance (GRP, n = 30), which was measured by considering individual performance for feed conversion ratio, Kleiber ratio, and pelt quality, and 2) based on female reproductive performance (FRP, CIEP-positive dams only, n = 36), which was measured by the number of kits alive 24h after birth. The pairwise fixation index, nucleotide diversity, and cross-population extended haplotype homozygosity were used to detect selection signatures. Only SNPs detected by at least two methods were considered selection signatures candidates, including 619, 569, and 526 SNPs for IRE, GRP, and FRP traits, respectively. The genes annotated from the candidate SNPs were associated with previously reported traits influenced by AD, including immune system process, growth, reproduction, and pigmentation. Notably, two olfactory-related gene ontology (GO) terms were significant (q < 0.05) for all studied traits, suggesting AD might cause loss of smell in infected mink. Additionally, the differences in genes and GO terms detected across different color types for IRE indicated that mink of different color types may differ in immune response to AD. The mitogen-activated protein kinase (MAPK) signalling pathway was significant (q < 0.05) in Kyoto Encyclopedia of Genes and Genomes pathway analyses for FRP, indicating AD infection may disorder the MAPK signalling pathway, in turn influencing female reproductive performance. Our study has enhanced the understanding of genomic architecture underlying resilience of mink to AD and sheds light on the underlying biological mechanisms involved.

  • Open Access

    A phase I dose-escalation study of neoantigen-activated haploidentical T cell therapy for the treatment of relapsed or refractory peripheral T-cell lymphoma

    by Yuan Chen, Hu Zhao, Jing Luo, Youping Liao, Xu Dan, Guoyu Hu, Weiyue Gu

    Peripheral T-cell lymphoma (PTCL) is a type of highly heterogeneous non-Hodgkin lymphoma with a poor prognosis and lack of effective targeted therapies. Adoptive T-cell therapy has been successfully used in the treatment of B-cell malignancies. We first used adoptive transfer of haploidentical T cells activated by patient-specific neoantigens in vitro to treat an elderly patient with refractory angioimmunoblastic T-cell lymphoma (AITL) in 2017, and the patient achieved long-term complete remission (CR). Here we report on early results from this first-in-human phase 1 clinical trial that aims to assess the safety and tolerability of neoantigen-activated haploidentical T cell therapy (NAHTC) for relapsed/refractory PTCL.Clinical trial registration: http://www.chictr.org.cn/index.aspx, identifier [ChiCTR1800017440].


  • Immunohistochemical evaluation and prognostic value of monocarboxylate transporter 1 (MCT1) and 4 (MCT4) in T-cell non-Hodgkin lymphoma

    by Hu Zhao, Yuan Chen, You-Ping Liao, Hai-Mei Chen, Qiu-Hong Yang, Yin Xiao, Jing Luo, Zhen-Zhen Chen, Lai Yi, Guo-Yu Hu

    Tumor cells often exhibit the Warburg effect, wherein, they preferentially undergo glycolysis over oxidative phosphorylation for energy production. Monocarboxylate transporter 1 (MCT1) and 4 (MCT4) are critical symporters mediating lactate efflux and preventing intracellular acidification during tumor growth. Numerous studies have focused on inhibiting MCT1 or MCT4 in various cancers. However, its role in T-cell lymphoma (TCL) is not yet investigated owing to the low incidence of TCL. This study was designed to investigate the expression of MCT1/MCT4 in patients with TCL and determine their prognostic value in this cancer. We performed immunohistochemistry to evaluate the expression level of MCT1/MCT4 in 38 TCL tissue samples and then compared their expression among different TCL subgroups, which were formed based on different clinical characteristics. Survival analysis was performed to evaluate the relationship between MCT1/MCT4 expression and both overall survival (OS) and progression-free survival (PFS). Our results revealed that MCT1 and MCT4 expression was significantly increased in TCL tissues compared to the control group. In addition, increased MCT1 expression associated with the female sex, advanced disease stage, increased serum LDH, Ki-67 at ≥ 50%, and intermediate or high-risk groups as categorized by the International Prognostic Index (IPI) score. We also found that increased MCT1 expression may be associated with reduced OS and PFS. In conclusion, MCT1 and MCT4 are overexpressed in patients with TCL and may predict poor prognosis. MCT1 inhibition might be a novel treatment strategy for TCL, and further preclinical trials are required.


  • Open Access

    Immunohistochemical Evaluation and Prognostic Value of Monocarboxylate Transporter 1 (MCT1) and 4 (MCT4) in T-cell Non-Hodgkin Lymphoma

    by Hu Zhao, Yuan Chen, You-Ping Liao, Hai-Mei Chen, Qiu-Hong Yang, Yin Xiao, Jing Luo, Zhen-Zhen Chen, Lai Yi, Guo-Yu Hu

    Tumor cells often exhibit the Warburg effect, wherein, they preferentially undergo glycolysis over oxidative phosphorylation for energy production. Monocarboxylate transporter 1 (MCT1) and 4 (MCT4) are critical symporters mediating lactate efflux and preventing intracellular acidification during tumor growth. Numerous studies have focused on inhibiting MCT1 or MCT4 in various cancers. However, its role in T-cell lymphoma (TCL) is not yet investigated owing to the low incidence of TCL. This study was designed to investigate the expression of MCT1/MCT4 in patients with TCL and determine their prognostic value in this cancer. We performed immunohistochemistry to evaluate the expression level of MCT1/MCT4 in 38 TCL tissue samples and then compared their expression among different TCL subgroups, which were formed based on different clinical characteristics. Survival analysis was performed to evaluate the relationship between MCT1/MCT4 expression and both overall survival (OS) and progression-free survival (PFS). Our results revealed that MCT1 and MCT4 expression was significantly increased in TCL tissues compared to the control group. In addition, increased MCT1 expression associated with the female sex, advanced disease stage, increased serum LDH, Ki-67 at ≥50%, and intermediate or high-risk groups as categorized by the International Prognostic Index (IPI) score. We also found that increased MCT1 expression may be associated with reduced OS and PFS. In conclusion, MCT1 and MCT4 are overexpressed in patients with TCL, and may predict poor prognosis. MCT1 inhibition might be a novel treatment strategy for TCL, and further preclinical trials are required.

  • Open Access

    A drug targeting 5‑lipoxygenase enhances the activity of a JAK2 inhibitor in CD34+ bone marrow cells from patients with JAK2V617F‑positive polycythemia vera in vitro

    by Yuan Chen, Hu Zhao, Jing Luo, Youping Liao, Kui Tan, Guoyu Hu

    Janus kinase 2 (JAK2) inhibitors, the first targeted treatments for myeloproliferative neoplasms (MPNs), provide substantial benefits, including a marked reduction in splenomegaly and MPN‑associated symptoms. However, these drugs rarely induce molecular remission in patients with MPNs. Zileuton, a 5‑lipoxygenase (5‑LO) inhibitor, has been demonstrated to selectively deplete hematopoietic stem cells (HSCs) expressing a JAK2 point mutation (JAK2V617F) in mouse models of JAK2V617F‑induced polycythemia vera (PV). To determine the potential activity of 5‑LO inhibitors in combination with JAK inhibitors against human PV HSCs, the present study first analyzed 5‑LO expression in CD34+ bone marrow cells from patients with JAK2V617F‑positive PV using western blotting and reverse transcription‑quantitative PCR, and then examined the effect of zileuton combined with ruxolitinib on colony formation using a colony formation assay. Furthermore, cell cycle and apoptosis in CD34+ cells from patients with PV and healthy volunteers were determined by flow cytometry. In the present study, 5‑LO expression was upregulated in CD34+ cells from patients with PV compared with in CD34+ cells from healthy volunteers. Higher levels of leukotriene B4, a product of the 5‑LO signaling pathway, were detected in patients with PV compared with in healthy volunteers. Zileuton treatment suppressed the colony formation of CD34+ cells from patients with PV in a dose‑dependent manner. Furthermore, zileuton and ruxolitinib exerted their anticancer effects by suppressing hematopoietic colony formation, inducing apoptosis and arresting the cell cycle of human CD34+ cells from patients with PV. The combination of these two drugs exerted a more beneficial effect than either agent alone. Based on these data, zileuton enhanced the antitumor activity of low‑dose ruxolitinib in hematopoietic progenitor cells from patients with PV, providing conceptual validation for further clinical applications of combination treatment with ruxolitinib and zileuton for patients with PV.


  • Breakpoint mapping of a t(9;22;12) chronic myeloid leukaemia patient with e14a3 BCR‐ABL1 transcript using Nanopore sequencing

    by Hu Zhao, Yuan Chen, Chanjuan Shen, Lingshu Li, Qingzhao Li, Kui Tan, Huang Huang, Guoyu Hu

    Background: The genetic changes in chronic myeloid leukaemia (CML) have been well established, although challenges persist in cases with rare fusion transcripts or complex variant translocations. Here, we present a CML patient with e14a3 BCR‐ABL1 transcript and t(9;22;12) variant Philadelphia (Ph) chromosome.Methods: Cytogenetic analysis and fluorescence in situ hybridization (FISH) was performed to identify the chromosomal aberrations and gene fusions. Rare fusion transcript was verified by a reverse transcription‐polymerase chain reaction (RT‐PCR). Breakpoints were characterized and validated using Oxford Nanopore Technologies (ONT) (Oxford, UK) and Sanger sequencing, respectively.Results: The karyotype showed the translocation t(9;22;12)(q34;q11.2;q24) [20] and FISH indicated 40% positive BCR‐ABL1 fusion signals. The RT‐PCR suggested e14a3 type fusion transcript. The ONT sequencing analysis identified specific positions of translocation breakpoints: chr22:23633040–chr9:133729579, chr12:121567595–chr22:24701405, which were confirmed using Sanger sequencing. The patient achieved molecular remission 3 months after imatinib therapy.Conclusions: The present study indicates Nanopore sequencing as a valid strategy, which can characterize breakpoints precisely in special clinical cases with atypical structural variations. CML patients with e14a3 transcripts may have good clinical course in the tyrosine kinase inhibitor era, as reviewed here.


  • Ruxolitinib for treatment of steroid-refractory graft-versus-host disease in adults: a systematic review and meta-analysis

    by Li Hui, Li Qi, Hu Guoyu, Shen Xuliang, Tan Meiao

    Objectives: Authors assessed the impact of ruxolitinib (RUX) on steroid-refractory graft-versus-host disease (SR-GVHD) patients. Methods: Studies published before January 2019 were identified by electronic search of MEDLINE, EMBASE, Cochrane Library, Clinical Trials.Gov and Web of Science databases. Results: Sixteen cohort studies (414 adults) were included whose methodological quality ranged from poor to good. Pooled outcomes such as the response rates, steroid dose reduction, 1-year overall survival, overall infection, and grade 3 to 4 cytopenia were calculated separately for adults with steroid-refractory acute GVHD (aGVHD) and chronic GVHD (cGVHD). Further, the overall response rates were analyzed according to the affected organ. Adults with aGVHD as well as cGVHD showed high response with RUX, and steroid dose reduction was observed in both cases. Infection rates and cytopenia were important safety concerns for both aGVHD and cGVHD. Conclusion: Notwithstanding the need of randomized controlled trials to confirm the effect of RUX on SR-GVHD, response rates among adults with aGVHD and cGVHD seem to be high with use of RUX as a salvage treatment, particularly in cases with gastrointestinal and cutaneous involvement. However, high rates of myelosuppression and infection remain a cause for concern regardless of aGVHD or cGVHD.